Dr. Jeffrey D. Wayne, MD
Internal Medicine (Internal Medicine Physician)
160 Gateway Dr Ste 100
Lincoln, CA 95648
Who else practices at this address →
Placer County includes primary care (12% of residents) and mental health (60% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1989, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license G65909 (first issued 1989; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrochlorothiazide Other prescribers in Lincoln, CA | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 10 payments worth $814 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $814 |
|---|
| Travel and Lodging | $588 |
|---|---|
| Food and Beverage | $225 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Travel and Lodging travel to Short Hills, NJ · in-kind Company’s descriptionResearch Related Service | $200 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionResearch Related Service | $134 |
| AstraZeneca Pharmaceuticals LP Jan 3, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionResearch Related Service | $111 |
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Travel and Lodging travel to Short Hills, NJ · in-kind Company’s descriptionResearch Related Service | $60.00 |
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Travel and Lodging travel to Short Hills, NJ · in-kind Company’s descriptionResearch Related Service | $60.00 |
| AstraZeneca Pharmaceuticals LP Oct 2, 2025 | Travel and Lodging travel to Short Hills, NJ · in-kind Company’s descriptionResearch Related Service | $23.75 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 28 industry-funded studies in 2025, from 9 companies. The companies reported $3,202,681 in research payments for these studies, mostly to the institutions running them.
- A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity
AstraZeneca Pharmaceuticals LP - A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morb…
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
AstraZeneca Pharmaceuticals LP - A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP - A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - TOL-CLAR-20024
Tolmar, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.